A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2021; you can also visit the original URL.
The file type is
Inadequate β-cell mass is essential for the pathogenesis of type 2 diabetes (T2D). Previous report showed that an immunomodulator FTY720, a sphingosine 1-phosphate (S1P) receptor modulator sustainably normalized hyperglycemia by stimulating β-cell in vivo regeneration in db/db mice. To further evaluate the therapeutic potential, we examined the effects of FTY720 on glucose homeostasis in a translational nonhuman primate (NHP) model of spontaneous diabetes. Daily administration of FTY720 (5doi:10.21203/rs.3.rs-289969/v1 fatcat:cvz7carkmff6nbpliqufgqxfpa